Tumor necrosis factor (TNF) synthesis is known to play a major part in numerous inflammatory disorders, and multiple transcriptional and post-transcriptional regulatory mechanisms have therefore evolved to dampen the production of this key proinflammatory cytokine 1,2 . The high expression of nicotinamide phosphoribosyltransferase (Nampt), an enzyme involved in the nicotinamide-dependent NAD biosynthetic pathway, in cells of the immune system 3 has led us to examine the potential relationship between NAD metabolism and inflammation. We show here that intracellular NAD concentration promotes TNF synthesis by activated immune cells. Using a positive screen, we have identified Sirt6, a member of the sirtuin family 4 , as the NAD-dependent enzyme able to regulate TNF production by acting at a post-transcriptional step. These studies reveal a previously undescribed relationship between metabolism and the inflammatory response and identify Sirt6 and the nicotinamidedependent NAD biosynthetic pathway as novel candidates for immunointervention in an inflammatory setting.
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NAD is an essential cofactor regulating numerous cellular metabolic pathways that has been recently recognized as a substrate for a growing number of NAD-dependent enzymes with multiple roles in cellular regulation 5, 6 . NAD-dependent protein modifications are catalyzed by several enzyme families, including polyADP ribosyltransferases (PARPs) and a family of deacetylases (sirtuins) with roles in a wide range of biological processes 4, 7 . A potential link between NAD and regulation of an inflammatory response is suggested by the expression profile of Nampt 3 , an enzyme involved in NAD biosynthesis from nicotinamide 8 . Nampt protein and/or mRNA levels were found to be upregulated upon stimulation of immune cells both in vivo and in vitro 9, 10 , whereas a specific Nampt inhibitor was found to inhibit cytokine production 11 , suggesting a functional link between NAD metabolism and inflammation. Notably, nicotinamide, an endogenous end-product inhibitor of NAD-consuming reactions, is known to inhibit the production of key inflammatory mediators [12] [13] [14] [15] . Finally, PARP-1, the founding member of the PARP family, has been shown to act as a transcriptional coactivator of nuclear factor-kB 16 , whereas mice lacking expression of this enzyme are protected from endotoxic shock 17, 18 . These and other observations engendered the view that PARP-1 may represent the molecular link between nicotinamide, NAD biosynthesis and secretion of proinflammatory cytokines through regulation of nuclear factor-kB transcriptional activity 16 .
To identify a functional link between intracellular NAD concentration and the control of an inflammatory response, we first analyzed the ability of the human monocytic THP-1 cell line (known to be able to use both nicotinamide and nicotinic acid as NAD precursors 19 ) to produce TNF in culture conditions affecting intracellular NAD concentration. THP-1 cells were incubated in control medium (containing nicotinamide as sole NAD precursor) or in medium supplemented with graded doses of APO866, a recently described and potent lowmolecular-weight inhibitor of Nampt known to affect intracellular NAD levels 19 . In keeping with previous observations 11 , a decrease in intracellular NAD levels was mirrored by a reduced capacity to produce TNF (and interleukin-6 (IL-6), Supplementary Fig. 1 online) in response to lipopolysaccharide (LPS; Fig. 1a ). NAD-deprived cells retained the ability to respond to LPS, as shown by the accumulation of the chemokine RANTES in the supernatant of activated cells (Fig. 1a) . Addition of nicotinamide mononucleotide, the product of the Nampt-catalyzed reaction, or exogenous nicotinic acid restored both intracellular NAD concentrations and TNF production in APO866-treated cells (Fig. 1b,c) . Notably, high doses of nicotinic acid led to a marked increase in intracellular NAD and supraoptimal TNF synthesis capacity (Fig. 1d) , confirming the existence of a functional link between intracellular NAD concentration and cytokine production in response to LPS. Repeated injections of APO866 significantly improved survival of mice undergoing polymicrobial sepsis and led to reduced serum amounts of TNF and IL-6, confirming the ability of this Nampt inhibitor to modulate inflammatory responses in vivo (Fig. 1e,f) .
In keeping with a putative role for a NAD-dependent enzymatic step in the control of an inflammatory response, nicotinamide was found to efficiently downmodulate cytokine production in response to LPS injection ( Supplementary Fig. 2a,b online) . When added to freshly isolated, splenic dendritic cells, exogenous nicotinamide was found to specifically inhibit TNF synthesis in response to CpG without affecting the capacity of these cells to secrete RANTES (Fig. 2a) or to upregulate expression of several maturation-associated molecules (Fig. 2b) . The inhibitory properties of this vitamin were independent of cell type and receptor stimulation ( Supplementary  Fig. 3 online) .
Despite some previously published evidence 17 , we dismissed a possible role for PARP-1 in regulating TNF production both in vivo and in vitro ( Supplementary Fig. 4 online) . In marked contrast, two structurally unrelated sirtuin inhibitors 20, 21 were found to inhibit TNF protein production with a minimal effect on RANTES synthesis and expression of cell surface markers (Fig. 2c,d ). Of note, cambinol showed a selective ability to inhibit TNF production both in vitro and in vivo (Fig. 2c,e and Supplementary Fig. 5 online) . Sirtuin and Nampt inhibitors were found to downregulate TNF protein production in response to LPS with only minimal effects on Tnf messenger RNA accumulation ( Fig. 3a and Supplementary Figure 6a online), suggesting a putative role for a sirtuin member in the posttranscriptional control of TNF expression. To circumvent any possible interference of nicotinamide with a transcriptional event, we stimulated macrophage cell lines with LPS for 2 h, washed the cells and subsequently incubated them in the presence of medium or nicotinamide for an additional 30 min. Nicotinamide strongly inhibited TNF protein synthesis in this setting, with minimal effect on the accumulation (Fig. 3b) and stability of Tnf transcripts ( Supplementary Fig. 6b ). A short pulse (30 min) of nicotinamide also led to a marked shift in the Tnf mRNA polysome profile (Fig. 3c) , indicating a possible interference of this vitamin with the Tnf mRNA translation efficacy, a finding further supported by a metabolic labeling experiment (Fig. 3d) and an ELISA evaluating both cell membrane-associated and soluble TNF ( Supplementary Fig. 6c ). Finally, nicotinamide selectively inhibited TNF synthesis driven by a constitutive viral promoter, eliminating any possible interference of nicotinamide with the TLR signaling cascade regulating gene transcription and mRNA splicing (Fig. 3e ).
An experimental strategy to positively identify the sirtuin member regulating TNF translation efficiency was next developed on the basis of the combined use of a TNF-encoding plasmid and a control, sirtuin-insensitive, mouse IL-2 reporter vector (see Supplementary  Fig. 7 online for expression analysis of transfected cell lines). Analysis of the relative expression of TNF versus IL-2 proteins in the supernatants of cell lines transfected with sirtuin-expressing constructs revealed a positive influence of Sirt6 on TNF protein synthesis (Fig. 4a,b ). The effect of nuclear sirtuins on TNF expression was analyzed in more detail (Fig. 4c,d ). Overexpression of wild-type Sirt6, but not the catalytically inactive form (Fig. 4e) , consistently resulted in increased TNF protein production relative to its mRNA levels ( Fig. 4d) . To confirm the role of Sirt6 in regulating TNF synthesis, we stimulated bone marrow-derived dendritic cells (BMDCs) from wildtype and Sirt6-knockout mice 22 in vitro with CpG and tested the supernatants for TNF content. Lack of Sirt6 expression decreased the capacity of BMDCs to produce TNF, confirming the role of this sirtuin member in regulating the production of TNF (Fig. 4f ).
We thus demonstrate that optimal TNF translation requires adequate intracellular NAD concentrations, revealing a potentially crucial link between cellular metabolites and inflammation. Low intracellular NAD amounts did not affect the ability of cells to produce RANTES, excluding a nonspecific effect of low NAD concentrations on gene expression and general protein synthesis. Although we initially hypothesized that a single molecular mechanism might explain the link between intracellular NAD levels and production of proinflammatory cytokines, our data suggest a complicated relationship between NAD metabolism and inflammation. Indeed, production of inflammatory cytokines is under the control of distinct biological pathways, as TNF production, but not IL-6 production, is sensitive to the sirtuin inhibitors used in this study ( Supplementary  Fig. 5 ). Further work will be required to identify the NAD-dependent and nicotinamide-sensitive process regulating IL-6 and IL-1b production in immune cells. Sirt6 was the only sirtuin member found to positively regulate TNF synthesis when transfected with a TNF-encoding plasmid. Although Sirt6 does not seem to bind Tnf mRNA (F.V.G., unpublished data) it shows some degree of selectivity toward this mRNA. In particular, we have confirmed that overexpression of Sirt6 does not affect IL-6 expression (data not shown), further stressing the specificity of Sirt6 in the control of TNF expression. The role of Sirt6 in regulating TNF production was further confirmed with inflammatory cells derived from Sirt6-knockout mice (Fig. 4f) . However, an in-depth analysis of the role of Sirt6 in vivo awaits the development of a mouse strain expressing a conditional allele of Sirt6, as Sirt6-knockout mice show multiple phenotypic abnormalities, including uncontrolled cell death and an altered immune system, that may nonspecifically affect an inflammatory response in vivo 22 . Only nuclear Sirt6 substrates have been identified to date 22, 23 , and further work will be required to identify the molecular mechanism underlying the observed effects of Sirt6 on Tnf mRNA translation. In any event, these observations suggest a role for Sirt6 in the regulation of Tnf mRNA translational efficiency and suggest new strategies for controlling inflammatory responses in vivo.
METHODS
Mice and in vivo experiments. We performed all mouse experiments in compliance with the relevant laws and institutional guidelines following approval by the Comité d'Ethique de l'Institut de Biologie et Médecine Moléculaire de l'Université Libre de Bruxelles. We injected mice (6-9 weeks of age) intravenously or intraperitoneally (i.p.) with LPS (Escherichia coli serotype 0111:B4), nicotinamide (both from Sigma), APO866 (previously identified as FK866 19 , synthesized and kindly provided by Astellas Pharma GmbH), cambinol 21 or the appropriate solvent. We performed cecal ligation and puncture (CLP) as previously described 24 and further detailed in the Supplementary Methods online. We administered APO866 (10 mg kg -1 ) intraperitoneally into mice twice daily for 3 d after CLP and monitored mouse survival for up to 2 weeks, or we killed them 24 h after surgery to collect blood for cytokine determination.
Purification and analysis of dendritic cells. We purified splenic dendritic cells from mice previously injected subcutaneously with 1 Â 10 6 B16 melanoma cells engineered to stably produce mouse Fms-like tyrosine kinase-3 by a magnetic positive selection procedure based on CD11c expression (Miltenyi Biotec). We generated BMDCs by culturing bone marrow precursors in granulocyte macrophage colony-stimulating factor-supplemented media as previously described 25 . We analyzed purified dendritic cells by flow cytometry with a FACSort (Becton Dickinson) with phycoerythrin-coupled antibodies to CD11c, CD40, CD80, CD86 or major histocompatibility complex class II (I-A d ), all purchased from BD Biosciences.
NAD and cytokine determinations. We cultured THP-1 cells (American Type Culture Collection, TIB-202) overnight with increasing doses of APO866, nicotinic acid or nicotinamide mononucleotide (both from Sigma) and stimulated them with 100 ng ml -1 LPS for 2 h or 1 mg ml -1 for 6 h. We determined intracellular NAD concentrations with an enzymatic cycling assay as previously described 26 and normalized the NAD values to protein concentrations (micro-BCA kit, Pierce). We determined cytokine concentrations with ELISA kits and/or antibody pairs from eBioscience (TNF), Biosource (IL-6), R&D Systems (RANTES) and BD Biosciences (IL-2, IL-10).
Plasmids, RNA extraction and analysis. We constructed C-terminal Flagtagged Sirts expression vectors after amplification of the corresponding coding sequences with primer sets containing Flag sequence (see Supplementary Methods for templates and primers sequences). We generated point mutants of Sirt6-Flag vectors (H113Y, in which His113 was substituted by a tyrosine residue) and Sirt7-FLAG vectors (H188Y, His188 to tyrosine) by site-directed mutagenesis with a standard PCR-based protocol and verified their integrity through DNA sequencing. We performed DNA transfection of the 293T cell line (American Type Culture Collection, CRL-11268) with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. We isolated total cellular RNA from cells with TRIZOL reagent (Invitrogen), and we reversetranscribed it with M-MLV reverse transcriptase using oligo(dT) primers (Invitrogen). We quantified specific mRNAs by SYBR Green (Eurogentec)-based RT-PCR with the ABI Prism 5700 sequence detection system (Applied Biosystems). The primers used for quantitative RT-PCR are listed in the Supplementary Methods. We normalized Tnf quantitative RT-PCR assays to the corresponding glyceraldehydes 3-phosphate dehydrogenase (Gapdh) or ribosomal protein L32 (Rpl32) mRNA levels. We purified and analyzed the mRNA associated with polysomes as described in the Supplementary Methods. ADP ribosylation assays, detection of ADP-ribosylated proteins and western blotting. We purified recombinant Flag-tagged Sirt1, Sirt2, Sirt3, Sirt4, Sirt5, Sirt6 and Sirt7 proteins by immunoprecipitation from transfected 293T cell lysates and eluted them with soluble Flag peptide (Sigma). To monitor the enzymatic activity of Sirt6, we incubated the immunoprecipitated wild-type or mutant forms of Sirt6 with etheno-NAD (Sigma) at 30 1C for 1 h, fractionated them by SDS-PAGE and transferred them to polyvinylidene fluoride membranes before immunoblot analysis. To detect transferred proteins, we incubated the polyvinylidene fluoride membranes with antibodies to Flag (M2), actin or etheno-adenosine (1G4), followed by the appropriate secondary reagents (all from Sigma). We performed the metabolic labeling of TNF as described in the Supplementary Methods.
Statistical analyses. For values with non-Gaussian distribution, we calculated the significance of differences with a two-tailed Mann-Whitney test. For normally distributed variables, we analyzed the significance of differences with a two-tailed Student's t-test. We generated survival curves by the Kaplan-Meier method and determined the significance of the survival rates by the log-rank test. All values are expressed as means ± s.d. We considered a difference between experimental groups as significant when the P value was o 0.05. All statistical analyses were calculated with Prism software (GraphPad Software, version 4).
Additional methods. Detailed methodology is described in the Supplementary Methods.
Note: Supplementary information is available on the Nature Medicine website.
